View this email in your browser ([link removed])
[link removed] July 8, 2026
** Best of AVAC’s Advocacy Guides
------------------------------------------------------------
Dear Advocate,
The AIDS 2026 ([link removed]) conference is fast approaching. To help advocates stay informed and engaged, AVAC has curated a collection of its Advocates' Guides covering the science, policy, implementation and advocacy conversations shaping the future of the HIV/AIDS response. Developed with partners across the field, these guides help translate complex science and policy to help inform advocacy before, during and after the conference.
For those presenting at AIDS 2026 ([link removed]) , please check out AVAC’s slide deck ([link removed]) containing the latest infographics on the research & development pipelines, the delivery of new prevention options and the impact of US funding cuts on foreign assistance and on research and science. We will be continuously updating it, so be sure to check back for updates as the conference approaches.
Advocates' checklist
[link removed]
The introduction of injectable lenacapavir for HIV PrEP (LEN) ([link removed]) is underway–in some places at least ([link removed]) . To ensure communities remain at the center of LEN rollout, this new Advocates' Checklist for Lenacapavir for PrEP Introduction ([link removed]) is an immediate, actionable blueprint. And read more in this blog ([link removed]) by the co-chairs of the Civil Society Caucus of the Coalition to Accelerate Access to Long-Acting PrEP ([link removed]) and AVAC staff ([link removed]) .
Access the Checklist > ([link removed])
Advocates' primer
[link removed]
Access The Guide > ([link removed])
web resource
[link removed]
** Planning For MK-8527
------------------------------------------------------------
Expanding prevention choice means investing in a diverse pipeline of HIV prevention options. MK-8527 is an investigational antiretroviral (ARV) once-monthly oral PrEP pill that is currently in Phase III clinical trials ([link removed]) . If proven safe and effective, it could offer another important PrEP option. This resource provides advocates with an overview of the MK-8527, the science behind it and the latest on its clinical development.
Learn More > ([link removed])
Download the Latest Infographics from AVAC
[link removed]
[link removed]
[link removed]
Presenting at AIDS2026?
infographics
[link removed]
These graphics are updated regularly, so be sure to check back.
access the graphics ([link removed])
Podcast: The Future of PrEP
Podcast
[link removed]
AVAC's Executive Director Mitchell Warren joined the Make Medicines Affordable ([link removed]) podcast to discuss the future of PrEP ([link removed]) . While Lenacapavir is a game-changing option for HIV prevention, Warren shares what it will take to ensure it reaches the people who need it most.
Listen Now ([link removed])
ADDITIONAL RESOURCES
• People’s Research Agenda ([link removed]) : This people-centered framework guides equitable and accelerated HIV prevention research, development and product introduction. It tracks scientific progress, assesses whether investments align with community-defined priorities, and identifies critical gaps in the prevention pipeline needed to meet the diverse needs and preferences of all populations
• HIV Prevention Product Overview ([link removed]) : The graphic provides an overview of PrEP products currently available and in late-stage clinical trials.
• Lenacapavir Resource Hub ([link removed]) : Your one-stop resource for all things lenacapavir, this page brings together the latest news, advocacy resources, scientific updates, implementation tools and infographics to help advocates stay informed and ensure LEN rolls out with speed, scale and equity.
In solidarity,
AVAC
P.S. On Tuesday, July 14 AVAC and partners will share the impact stories of ten years of the Coalition to Accelerate and Support Prevention Research (CASPR) ([link removed]) . We hope you’ll join us ([link removed]) .
Follow us @hivpxresearch ([link removed])
[link removed] [link removed] [link removed]
Share this issue ([link removed])
AVAC Global Advocacy for HIV Prevention
+1 212 796 6423
[email protected] (mailto:
[email protected]) www.avac.org ([link removed])
You're receiving this because you signed up for our newsletter. Not interested any longer?
Manage email preferences ([link removed]) | Unsubscribe ([link removed])
